185 related articles for article (PubMed ID: 25353187)
21. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
Molica S
Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
[TBL] [Abstract][Full Text] [Related]
22. Disappearance of B-Symptoms In Comorbid Patients Receiving First-Line Obinutuzumab (Ga101) -Chlorambucil (G-Clb) Or Rituximab-Chlorambucil (R-Clb) for Chronic Lymphocytic Leukemia (Cll).
Wenk AS; Becker U; Klawitter S; Wiesner C; Bernhardt A
Value Health; 2014 Nov; 17(7):A522. PubMed ID: 27201638
[No Abstract] [Full Text] [Related]
23. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
24. Expression of CD11a (LFA-1) on B-chronic Lymphocytic Leukemia and Lymphoma Cells: Correlation with Cell Surface Immunoglobulin Intensity and CD58 (LFA-3) Expression.
Rabinowitz R; Polliack A; Leizerowitz R; Keren-Zur Y; Schlesinger M
Leuk Lymphoma; 1991; 5 Suppl 1():59-64. PubMed ID: 27463481
[TBL] [Abstract][Full Text] [Related]
25. Chronic lymphocytic leukemia in (Richter's) transformation.
Giles FJ; O'Brien SM; Keating MJ
Semin Oncol; 1998 Feb; 25(1):117-25. PubMed ID: 9482533
[TBL] [Abstract][Full Text] [Related]
26. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study.
Brewer JD; Shanafelt TD; Otley CC; Roenigk RK; Cerhan JR; Kay NE; Weaver AL; Call TG
J Clin Oncol; 2012 Mar; 30(8):843-9. PubMed ID: 22331952
[TBL] [Abstract][Full Text] [Related]
27. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.
Li J; Zhi J; Wenger M; Valente N; Dmoszynska A; Robak T; Mangat R; Joshi A; Visich J
J Clin Pharmacol; 2012 Dec; 52(12):1918-26. PubMed ID: 22235140
[TBL] [Abstract][Full Text] [Related]
29. Obinutuzumab for the treatment of lymphoproliferative disorders.
Owen C; Stewart DA
Expert Opin Biol Ther; 2012 Mar; 12(3):343-51. PubMed ID: 22283718
[TBL] [Abstract][Full Text] [Related]
30. No evidence for anticipation in lymphoproliferative tumors in population-based samples.
Daugherty SE; Pfeiffer RM; Mellemkjaer L; Hemminki K; Goldin LR
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1245-50. PubMed ID: 15894680
[TBL] [Abstract][Full Text] [Related]
31. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
32. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
33. Rituximab for chronic lymphocytic leukemia.
Robak T
Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
[TBL] [Abstract][Full Text] [Related]
34. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
35. Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.
García-Muñoz R; Nájera MJ; Feliu J; Antón-Remírez J; Ramalle-Gómara E; Marín-Gorricho R; Peralta R; Gutiérrez-Gamarra E; Nuñez-Rodriguez J; Zafra-Morales R; Aguinaga L; Nebot-Villacampa MJ; Hernandez-Pérez PM; Farfán-Quiroga G; Panizo C; Domínguez-Garrido E
Future Sci OA; 2019 Nov; 5(10):FSO425. PubMed ID: 31827894
[TBL] [Abstract][Full Text] [Related]
36. Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells.
Latour S; Zanese M; Le Morvan V; Vacher AM; Menard N; Bijou F; Durrieu F; Soubeyran P; Savina A; Vacher P; Bresson-Bepoldin L
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30832225
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.
Decaup E; Jean C; Laurent C; Gravelle P; Fruchon S; Capilla F; Marrot A; Al Saati T; Frenois FX; Laurent G; Klein C; Varoqueaux N; Savina A; Fournié JJ; Bezombes C
Blood Cancer J; 2013 Aug; 3(8):e131. PubMed ID: 23933705
[TBL] [Abstract][Full Text] [Related]
38. Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.
Baer Ii WH; Maini A; Jacobs I
Pharmaceuticals (Basel); 2014 May; 7(5):530-44. PubMed ID: 24810947
[TBL] [Abstract][Full Text] [Related]
39. Chronic Lymphocytic Leukemia as an Unusual Cause of Rapid Airway Compromise.
Bersabe AR; Romain JT; Ezzell EE; Renshaw JS
Case Rep Oncol Med; 2017; 2017():8247353. PubMed ID: 28396813
[TBL] [Abstract][Full Text] [Related]
40. GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption.
Bakkour W; Coulson IH
Dermatol Ther (Heidelb); 2012 Dec; 2(1):3. PubMed ID: 23205326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
